HIGH TIDE INC (HITI.CA) Stock Fundamental Analysis
TSX-V:HITI - TSX Venture Exchange - CA42981E4013 - Common Stock - Currency: CAD
Overall HITI gets a fundamental rating of 4 out of 10. We evaluated HITI against 35 industry peers in the Pharmaceuticals industry. While HITI seems to be doing ok healthwise, there are quite some concerns on its profitability. HITI is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
HITI had negative earnings in the past year.
In the past year HITI had a positive cash flow from operations.
HITI had negative earnings in each of the past 5 years.
HITI had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
HITI has a Return On Assets (-4.17%) which is comparable to the rest of the industry.
HITI's Return On Equity of -6.91% is fine compared to the rest of the industry. HITI outperforms 60.61% of its industry peers.
HITI has a Return On Invested Capital of 4.75%. This is amongst the best in the industry. HITI outperforms 87.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.17% | ||
| ROE | -6.91% | ||
| ROIC | 4.75% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HITI's Operating Margin of 2.22% is fine compared to the rest of the industry. HITI outperforms 72.73% of its industry peers.
HITI has a Gross Margin of 25.83%. This is in the lower half of the industry: HITI underperforms 69.70% of its industry peers.
HITI's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.22% | ||
| PM (TTM) | N/A | ||
| GM | 25.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), HITI is destroying value.
Compared to 1 year ago, HITI has more shares outstanding
HITI has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, HITI has an improved debt to assets ratio.
2.2 Solvency
HITI has an Altman-Z score of 3.08. This indicates that HITI is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 3.08, HITI belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
HITI has a debt to FCF ratio of 4.52. This is a neutral value as HITI would need 4.52 years to pay back of all of its debts.
HITI has a Debt to FCF ratio of 4.52. This is amongst the best in the industry. HITI outperforms 84.85% of its industry peers.
HITI has a Debt/Equity ratio of 0.30. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of HITI (0.30) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 4.52 | ||
| Altman-Z | 3.08 |
ROIC/WACC0.54
WACC8.82%
2.3 Liquidity
A Current Ratio of 1.57 indicates that HITI should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.57, HITI is in line with its industry, outperforming 48.48% of the companies in the same industry.
HITI has a Quick Ratio of 1.57. This is a bad value and indicates that HITI is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of HITI (0.97) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 0.97 |
3. Growth
3.1 Past
The earnings per share for HITI have decreased strongly by -1957.14% in the last year.
The Revenue has grown by 9.22% in the past year. This is quite good.
The Revenue has been growing by 75.59% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-1957.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1233.33%
Revenue 1Y (TTM)9.22%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%10.9%
3.2 Future
Based on estimates for the next years, HITI will show a very strong growth in Earnings Per Share. The EPS will grow by 74.44% on average per year.
Based on estimates for the next years, HITI will show a quite strong growth in Revenue. The Revenue will grow by 11.55% on average per year.
EPS Next Y11.83%
EPS Next 2Y68.97%
EPS Next 3Y65.89%
EPS Next 5Y74.44%
Revenue Next Year11.99%
Revenue Next 2Y11.69%
Revenue Next 3Y13.18%
Revenue Next 5Y11.55%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for HITI. In the last year negative earnings were reported.
HITI is valuated quite expensively with a Price/Forward Earnings ratio of 58.30.
HITI's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. HITI is cheaper than 72.73% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 37.67. HITI is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 58.3 |
4.2 Price Multiples
84.85% of the companies in the same industry are more expensive than HITI, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, HITI is valued a bit cheaper than 75.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.18 | ||
| EV/EBITDA | 8.1 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as HITI's earnings are expected to grow with 65.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y68.97%
EPS Next 3Y65.89%
5. Dividend
5.1 Amount
HITI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:HITI (7/25/2025, 7:00:00 PM)
3.14
-0.08 (-2.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners7.98%
Inst Owner ChangeN/A
Ins Owners8.81%
Ins Owner ChangeN/A
Market Cap254.97M
Analysts80
Price Target7.14 (127.39%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-9.69%
Min EPS beat(2)-11.37%
Max EPS beat(2)-8%
EPS beat(4)1
Avg EPS beat(4)-48.88%
Min EPS beat(4)-315.76%
Max EPS beat(4)139.6%
EPS beat(8)5
Avg EPS beat(8)27.56%
EPS beat(12)9
Avg EPS beat(12)32.7%
EPS beat(16)11
Avg EPS beat(16)20.33%
Revenue beat(2)1
Avg Revenue beat(2)0.05%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)1.6%
Revenue beat(4)3
Avg Revenue beat(4)0.79%
Min Revenue beat(4)-1.49%
Max Revenue beat(4)1.9%
Revenue beat(8)5
Avg Revenue beat(8)0.38%
Revenue beat(12)9
Avg Revenue beat(12)1.89%
Revenue beat(16)13
Avg Revenue beat(16)7.54%
PT rev (1m)0%
PT rev (3m)2.44%
EPS NQ rev (1m)28.55%
EPS NQ rev (3m)28.55%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0.64%
Revenue NQ rev (3m)0.64%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 58.3 | ||
| P/S | 0.46 | ||
| P/FCF | 18.18 | ||
| P/OCF | 10.28 | ||
| P/B | 1.82 | ||
| P/tB | 5.15 | ||
| EV/EBITDA | 8.1 |
EPS(TTM)-0.13
EYN/A
EPS(NY)0.05
Fwd EY1.72%
FCF(TTM)0.17
FCFY5.5%
OCF(TTM)0.31
OCFY9.73%
SpS6.78
BVpS1.72
TBVpS0.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.17% | ||
| ROE | -6.91% | ||
| ROCE | 6.6% | ||
| ROIC | 4.75% | ||
| ROICexc | 5.86% | ||
| ROICexgc | 14.81% | ||
| OM | 2.22% | ||
| PM (TTM) | N/A | ||
| GM | 25.83% | ||
| FCFM | 2.55% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
F-Score5
Asset Turnover2.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 4.52 | ||
| Debt/EBITDA | 1.22 | ||
| Cap/Depr | 47.33% | ||
| Cap/Sales | 1.96% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 70.95% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 0.97 | ||
| Altman-Z | 3.08 |
F-Score5
WACC8.82%
ROIC/WACC0.54
Cap/Depr(3y)28.99%
Cap/Depr(5y)34.63%
Cap/Sales(3y)1.88%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1957.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1233.33%
EPS Next Y11.83%
EPS Next 2Y68.97%
EPS Next 3Y65.89%
EPS Next 5Y74.44%
Revenue 1Y (TTM)9.22%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%10.9%
Revenue Next Year11.99%
Revenue Next 2Y11.69%
Revenue Next 3Y13.18%
Revenue Next 5Y11.55%
EBIT growth 1Y37.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year316.17%
EBIT Next 3Y105.72%
EBIT Next 5Y69.76%
FCF growth 1Y182.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y110.28%
OCF growth 3YN/A
OCF growth 5YN/A